To the Editor A recent randomized clinical trial reported that after induction chemotherapy (IC), patients with stages III to IVB (American Joint Committee on Cancer Staging Manual, 7th Edition) nasopharyngeal carcinoma (NPC) receiving radiation therapy alone had noninferior oncologic outcomes and fewer acute adverse events, compared with those receiving concurrent chemoradiotherapy (CCRT). We have several comments about this impactful study.
Risultati per: Linee guida per la gestione del carcinoma epatocellulare negli adulti
Questo è quello che abbiamo trovato per te
Standardizing Retrospective Observational Research in Cutaneous Squamous Cell Carcinoma
This Consensus Statement develops recommendations for reporting measures and types of statistical analyses to be used in retrospective observational studies of cutaneous squamous cell carcinoma.
Chemotherapy, Radiation Therapy, and Nasopharyngeal Carcinoma
To the Editor We read the article by Dai et al with great interest. Omitting chemotherapy in patients receiving induction chemotherapy (IC) is a hot topic in nasopharyngeal carcinoma treatment, particularly in the intensity-modulated radiotherapy era. Yet, concurrent cisplatin is still recommended in advanced-stage disease, and the cumulative dose of concurrent cisplatin recommended is at least 200 mg/m2 in the latest American Society of Clinical Oncology/Chinese Society of Clinical Oncology guidelines. The authors in the current study gave 30-mg/m2 cisplatin per week and only 12.1% of patients had received 7 weeks of cisplatin, which makes a total 210 mg/m2. For patients receiving IC, at least a total 160-mg/m2 dose of cisplatin is recommended, which had been received by 85.8% of patients. Could the inadequate cumulative concurrent cisplatin dose be the reason why the IC in combination with radiotherapy (IC-RT) arm was noninferior to the IC with induction chemotherapy combined with chemoradiotherapy (IC-CCRT) arm? Therefore, we would kindly like the authors to separately analyze the results of patients receiving adequate doses of concurrent cisplatin.
Linee guida sull’identificazione e gestione dell’insufficienza surrenalica
Sindromi coronariche, la cardiologa italiana firma le linee guida Ue
Felicita Andreotti: ‘Principale causa morte in adulti nel mondo’
Ruolo della denervazione renale nella gestione dell’ipertensione
Linee guida 2024 per la gestione dell’ipertensione arteriosa
Linee guida sulla terapia con ossigeno domiciliare per adulti
Linee guida per il trattamento dell’emofilia congenita A e B
Linee guida sulla valutazione, diagnosi, cura e supporto per le persone con demenza
Gestione dei pazienti con malattia coronarica cronica: linea guida
Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma
New England Journal of Medicine, Volume 391, Issue 8, Page 710-721, August 22/29, 2024.
Certificati e vaccini, guida per viaggiare con i propri animali
La richiesta del passaporto ai servizi veterinari delle asl
Linee guida sulla gestione del cancro al retto.
BSG: linee guida per la gestione del carcinoma epatocellulare negli adulti
Pelle, capelli,unghie e occhi. Guida per un'estate senza pensieri
Proteggere il cuoio capelluti e curare l’igiene delle lenti